Imunon, Inc. (NASDAQ:IMNN) Short Interest Update

Imunon, Inc. (NASDAQ:IMNN) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 193,639 shares, an increase of 114.2% from the August 31st total of 90,383 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average daily trading volume, of 154,079 shares, the short-interest ratio is currently 1.3 days.

Imunon Stock Performance

NASDAQ IMNN traded down $0.04 on Tuesday, reaching $1.33. 157,140 shares of the company’s stock traded hands, compared to its average volume of 99,206. The firm has a market cap of $7.49 million, a price-to-earnings ratio of -0.35 and a beta of 1.98. The stock has a 50 day moving average price of $1.54 and a 200-day moving average price of $2.12. Imunon has a fifty-two week low of $1.29 and a fifty-two week high of $5.55. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.82 and a current ratio of 1.82.

Imunon (NASDAQ:IMNN) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.33. Equities research analysts predict that Imunon will post -2.37 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a research note on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

About Imunon

Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies for the treatment of cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes or immune-stimulating agents directly to targeted tissues, with the goal of activating the body’s immune response against disease.

Its leading product candidate is IMNN-001, formerly known as GEN-1, an investigational DNA-based interleukin-12 immunotherapy being developed for advanced ovarian cancer.